STOCK TITAN
  1. Home
  2. News
  3. PCVX

Vaxcyte, Inc. - PCVX STOCK NEWS

Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.

Vaxcyte, Inc. (Nasdaq: PCVX) is a pioneering biopharmaceutical company based in San Carlos, California, dedicated to developing high-fidelity vaccines to protect against serious bacterial infections. Vaxcyte aims to improve global health through innovative vaccines designed to prevent diseases that conventional options fail to address effectively.

The company's flagship product, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) designed to provide broad-spectrum protection against invasive pneumococcal disease (IPD). VAX-24 is engineered to cover more strains than the current leading vaccines, addressing a significant unmet need in both adult and pediatric populations. Vaxcyte's advanced cell-free protein synthesis platform, XpressCF™, is pivotal in developing these complex conjugate vaccines, allowing for efficient production and enhanced immunogenicity.

Vaxcyte's pipeline includes VAX-31, a next-generation 31-valent PCV, currently in Phase 1/2 clinical trials. VAX-31 aims to achieve the broadest coverage of any PCV to date, targeting 95% of IPD strains circulating in the U.S. adult population. Additionally, the company is developing other promising vaccine candidates such as VAX-A1 for Group A Strep infections, VAX-PG for periodontal disease, and VAX-GI for Shigella prevention.

Recent milestones include the successful completion of enrollment in the VAX-31 Phase 1/2 trial and the VAX-24 infant Phase 2 study. The FDA granted Breakthrough Therapy designation to VAX-24, reflecting its potential to offer substantial improvements over existing treatments. Vaxcyte is on track to advance VAX-24 into Phase 3 trials, with topline data anticipated by 2025.

Financially, Vaxcyte is robust, supported by $1.4 billion in recent follow-on equity financings to advance its vaccine candidates and expand its manufacturing capabilities.

For more information, visit www.vaxcyte.com.

News

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) completes enrollment in Phase 1/2 study for VAX-31, a potential best-in-class pneumococcal conjugate vaccine franchise, with topline safety, tolerability, and immunogenicity data expected in Q3 2024. VAX-31 aims to provide coverage for 95% of IPD circulating in the U.S. adult population, addressing a significant public health need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
clinical trial
-
News

Vaxcyte Appoints Whitney Jones as Chief People Officer

Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) appoints Whitney Jones as Chief People Officer to lead human resources strategy and operations, emphasizing a people-first approach to support organizational growth strategies and advance vaccine candidates, including lead pneumococcal conjugate vaccine franchise programs, VAX-24 and VAX-31.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
management
-
News

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Rhea-AI Summary
Vaxcyte, Inc. (PCVX) Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Study, Plans for Phase 3 Pivotal Study and Receives Encouraging Input on CMC Licensure Requirements; Enrollment in VAX-24 Infant Phase 2 Study Progressing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.07%
Tags
none
News

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Rhea-AI Summary
Vaxcyte, Inc. (PCVX) published results from the VAX-24 Phase 1/2 clinical proof-of-concept study in The Lancet Infectious Diseases. The study demonstrated that VAX-24 had a safety and tolerability profile similar to Prevnar 20® (PCV20) at all doses studied and met or exceeded regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 mcg dose. The company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program, with topline data expected in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
clinical trial
-
News

Vaxcyte Appoints Jacks Lee to Board of Directors

Rhea-AI Summary
Vaxcyte, a vaccine innovation company (Nasdaq: PCVX), appointed Jacks Lee to its Board of Directors. The company aims to develop high-fidelity vaccines for bacterial diseases. The appointment aims to leverage Jacks Lee's expertise in biopharmaceutical and vaccine manufacturing, supply, and operations to advance the development and potential global commercialization of Vaxcyte's pneumococcal conjugate vaccine (PCV) candidates, VAX-24 and VAX-31.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
management
-
News

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Rhea-AI Summary
Vaxcyte, Inc. (PCVX) obtains exclusive rights to develop and manufacture cell-free extract, a key component of the company’s pneumococcal conjugate vaccine (PCV) franchise. This strengthens Vaxcyte’s global commercial manufacturing strategy as lead PCV candidate, VAX-24, advances into Phase 3. Vaxcyte exercised its option and entered into a manufacturing rights agreement with Sutro Biopharma, Inc. (STRO) to obtain control over the development and manufacture of cell-free extract for its vaccine candidates. The agreement involves a $50 million cash payment to Sutro, with an additional $25 million to be paid within six months, and potential milestone payments totaling up to $60 million in cash upon the occurrence of certain regulatory milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
News

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Rhea-AI Summary
PCVX - Vaxcyte, Inc. Announces Initiation of Phase 1/2 Clinical Study for VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine Candidate, with Broadest-Spectrum Coverage and Topline Safety Data Expected in Second Half of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
clinical trial
-
News

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Vaxcyte, Inc. has announced financial results for Q3 2023 and provided a business update. The company completed a successful End-of-Phase 2 meeting with the FDA for VAX-24, with topline Phase 3 data expected in 2025. They also received FDA clearance for VAX-31 Adult IND Application, with Phase 1/2 study initiation expected this quarter and topline data in the second half of 2024. Vaxcyte has advanced the ongoing VAX-24 Infant Phase 2 study, with topline data expected by 2025. They have also expanded their collaboration with Lonza for global commercial manufacturing of VAX-24 and VAX-31. As of September 30, 2023, the company has $1.4 billion in cash, cash equivalents, and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
earnings
-
News

Vaxcyte to Present at Upcoming Investor Conferences

Rhea-AI Summary
Vaxcyte, Inc. will participate in investor conferences including Guggenheim 5th Annual Inflammation & Immunology Conference, Jefferies London Healthcare Conference, and Evercore ISI 6th Annual HealthCONx Conference. The fireside chats will be live-streamed on the company's website and replays will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
News

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Rhea-AI Summary
Vaxcyte receives FDA clearance for adult IND application of VAX-31 pneumococcal conjugate vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
clinical trial

FAQ

What is the current stock price of Vaxcyte (PCVX)?

The current stock price of Vaxcyte (PCVX) is $85.91 as of December 24, 2024.

What is the market cap of Vaxcyte (PCVX)?

The market cap of Vaxcyte (PCVX) is approximately 10.7B.

What is Vaxcyte, Inc.'s primary focus?

Vaxcyte is focused on developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

What are the key products in Vaxcyte's pipeline?

Vaxcyte's key products include VAX-24, a 24-valent pneumococcal conjugate vaccine, and VAX-31, a 31-valent PCV, along with other candidates like VAX-A1, VAX-PG, and VAX-GI.

What makes VAX-24 different from existing vaccines?

VAX-24 is designed to provide broader protection against more pneumococcal strains compared to current vaccines, addressing significant unmet needs in both adults and children.

What is the XpressCF™ platform?

XpressCF™ is Vaxcyte's cell-free protein synthesis platform that allows efficient production of complex vaccines with enhanced immunogenic benefits.

What recent milestones has Vaxcyte achieved?

Recent milestones include the completion of enrollment in the VAX-31 Phase 1/2 trial and the VAX-24 infant Phase 2 study, along with FDA Breakthrough Therapy designation for VAX-24.

When is Vaxcyte expected to release data from its VAX-24 Phase 3 trials?

Vaxcyte plans to release topline data from the VAX-24 Phase 3 trials by 2025.

What financial support does Vaxcyte have for its projects?

Vaxcyte is financially supported by recent equity financings totaling approximately $1.4 billion.

Where can I find more information about Vaxcyte?

For more information, you can visit Vaxcyte's official website at www.vaxcyte.com.

What is VAX-31 and its significance?

VAX-31 is a 31-valent pneumococcal conjugate vaccine aiming to cover 95% of invasive pneumococcal disease strains in the U.S. adult population, representing the broadest coverage in PCV candidates.

What other vaccine candidates is Vaxcyte developing?

Besides VAX-24 and VAX-31, Vaxcyte is developing VAX-A1 for Group A Strep, VAX-PG for periodontal disease, and VAX-GI for Shigella.

Stock PCVX logo
Vaxcyte, Inc.

Nasdaq:PCVX

PCVX Rankings

#824 Ranked by Market Cap
N/A Ranked by Dividends

PCVX Stock Data

10.71B
120.72M
0.49%
112.31%
7.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN CARLOS